🟢 Teva Pharmaceuticals up 5% on continued positive sentiment from WELTRUZA™ FDA approval

Teva Pharmaceuticals is trading at ILA 12610.00, up 5.08%. The rise follows continued positive market reaction to the FDA approval of WELTRUZA™ (olanzapine) for extended-release injectable suspension, a new, once-monthly, subcutaneous long-acting injectable for the treatment of schizophrenia in adults. The approval, announced Friday, October 9, 2026, positions WELTRUZA™ as the first and only once-monthly subcutaneous olanzapine LAI, expected to be available in the U.S. in the coming weeks.